As Vice President, Translational Medicine, Asher Schachter is responsible for shepherding preclinical assets through clinical proof-of-concept. Asher joined Visterra in 2020. Prior to moving to industry, Asher practiced clinical pediatric nephrology at Boston Children’s Hospital. During his time there, he conducted translational research on focal segmental glomerulosclerosis (FSGS), and recurrence of FSGS after kidney transplantation. Subsequently, Asher joined the Translational Medicine group at the Novartis Institutes for BioMedical Research as the medical lead on early clinical development programs. He then joined CAMP4 Therapeutics as Translational Medicine lead covering several disease areas.
Asher received his MD from the University of Toronto, completed his pediatric residency at Toronto’s Hospital for Sick Children, and his pediatric nephrology fellowship at Boston Children’s Hospital. Asher received his MMSc (Medical Science), and MSc (Medical Informatics) from the Harvard-MIT Division of Health Sciences and Technology. Subsequently, Asher was a Sloan Industry Center fellow at MIT where he furthered his thesis work building a Bayesian network model of success in drug development.
